Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: Biochem Pharmacol. 2018 Oct 4;158:103–113. doi: 10.1016/j.bcp.2018.10.003

Figure 3:

Figure 3:

Figure 3:

Figure 3:

Figure 3:

Figure 3:

Figure 3:

Comparison of the Emax relative to that of NECA (arbitrarily set at 100%) (A) and negative logEC50 (B) of nineteen synthetic A3AR ligands tested with the stable hA3AR-NanoBit®-βarr2 HEK293T cell line (Barr2) versus the stable hA3AR CHO cell line (cAMP).